Australia's Pharmaxis Says CF Drug Results Point To U.S. Application
This article was originally published in PharmAsia News
Executive Summary
Pharmaxis of Australia said final-stage trial results for its Bronchitol (mannitol) drug for cystic fibrosis were successful enough to file for U.S. approval